José Antonio Franchini Ramirez
University of São Paulo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by José Antonio Franchini Ramirez.
Arquivos Brasileiros De Cardiologia | 2008
Christiano Pereira Silva; Carlo Henrique Del Carlo; Mucio Tavares de Oliveira Junior; Airton R. Scipioni; Celia Strunz-Cassaro; José Antonio Franchini Ramirez; Antonio Carlos Pereira Barretto
BACKGROUND: Heart failure is a highly prevalent disease, the prognosis of which depends on different predictive factors. OBJECTIVE: Chagas disease is a predictor of poor prognosis in patients with chronic heart failure (HF). The purpose of this study is to investigate whether this condition also predicts poor outcome in acutely decompensated patients. METHODS: Four hundred and seventeen patients admitted for decompensated heart failure were studied. Mean age was 51.8 years, and 291 (69.8%) were male. They were divided into two groups: 133 (31.9%) patients with Chagas heart disease (CH) and 284 patients with heart failure of other etiologies. Cytokine and norepinephrine plasma levels were measured in a subgroup of 63 patients (15.1% with Chagas disease). RESULTS: At admission, 24.6% of the patients needed inotropic support, and one-year mortality was 54.7%. Mortality rates were higher in the CH group (69.2% vs. 47.9%, p < 0.001). When data were compared, patients with Chagas disease were younger (47.6 vs. 53.8 years, p < 0.001) and, on average, showed lower systolic blood pressure (96.7 vs. 111.2 mmHg, p < 0,001), ejection fraction (32.7 vs. 36.4%, p < 0.001), and serum Na (134.6 vs. 136.0, p = 0.026), in addition to higher TNF-α levels (33.3 vs. 14.8, p = 0.001). The presence of hypotension requiring inotropic support, left ventricular (LV) diastolic diameter, renal function findings, and interleukin-6 and norepinephrine plasma levels did not differ between both groups. CONCLUSION: Chagas disease patients admitted with decompensated heart failure had worse prognoses than patients with heart failure of other etiologies. This may be owing to a greater degree of cardiac impairment (lower ejection fraction) and hemodynamic instability (lower systolic blood pressure and heart rate), increased activation of the renin-angiotensin system (lower sodium), and increased cytokine levels (TNF-α).
Resuscitation | 2003
Edison Ferreira de Paiva; Maria Beatriz Perondi; Karl B. Kern; Robert A. Berg; Sergio Timerman; Luiz Francisco Cardoso; José Antonio Franchini Ramirez
OBJECTIVE Amiodarone has been shown to be superior to both placebo and lidocaine in improving survival to hospital admission for victims of out-of-hospital refractory ventricular fibrillation. Concern had been expressed about the known vasodilatatory effects of amiodarone if given without precedent vasoconstrictive medications. The haemodynamic effects of intravenous amiodarone administered during ongoing CPR have not been systemically investigated. Our intention was to verify if amiodarone alone produced significantly lower resuscitation haemodynamics than did either adrenaline (epinephrine) alone or the combination of amiodarone and adrenaline. DESIGN Prospective, randomized, comparative study. SETTING Research laboratory of a medical school. SUBJECTS Thirty mongrel dogs. INTERVENTIONS After 8 min of untreated VF, defibrillation was attempted once at 3 J/kg and external chest compressions and ventilation started. Those animals resistant to the defibrillation attempt were randomized, ten to an adrenaline (0.02 mg/kg) group, ten to an amiodarone (5 mg/kg) group, and ten to a group receiving a combination of both drugs. MEASUREMENTS AND MAIN RESULTS Aortic systolic and diastolic, and coronary perfusion pressures were all significantly lower in the group receiving amiodarone alone than in the other two groups. Amiodarone combined with adrenaline produced pressures during CPR similar to adrenaline alone. CONCLUSION Amiodarone can be safely administered simultaneously in combination with adrenaline and such a combination results in similar haemodynamic support as adrenaline alone. Amiodarone administered alone produces significantly lower coronary perfusion pressure than when combined with adrenaline.
Arquivos Brasileiros De Cardiologia | 1998
Rafael Leite Luna; Wille Oigman; José Antonio Franchini Ramirez; Décio Mion; Michel Batlouni; João Rocha; Gilson Soares Feitosa; Iran Castro; Hilton de Castro Chaves Júnior; Epotamenides Maria Good God; Lilia Nigro Maia; Katia Coelho Ortega; Angela Raineri
PURPOSE Multicenter, open and non-controlled study to evaluated the efficacy and the tolerability of a low-dose combination of two anti-hypertensive agents: a cardioselective beta-blocker, bisoprolol (2.5 and 5.0 mg) with 6.25 mg of hydrochlorothiazide. METHODS One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial. RESULTS The bisoprolol/hydrochlorothiazide combination reduced the initial mean values of systolic and diastolic blood pressures, respectively, from the 157.4 mmHg and 98.8 mmHg to 137.3 mmHg and 87.4 mmHg. At the end of the treatment period, 61% of the patients normalized blood pressure values (< 90 mmHg) and 22.9% of them had responded to the treatment, resulting in a total response rate (normalized + responsive) of 83.9% of cases. Adverse events were described only in 18.9% of the patients and dizziness and headache were the most common. There were no clinically significant changes on plasma levels of potassium, uric acid, glucose, or in the lipid profile. CONCLUSION The combination of low dosages of bisoprolol and hydrochlorothiazide may be considered an effective, well tolerated and rational alternative for the initial treatment of the patients with mild to moderate hypertension.PURPOSE: Multicenter, open and non-controlled study to evaluated the efficacy and the tolerability of a low-dose combination of two anti-hypertensive agents: a cardioselective beta-blocker, bisoprolol (2.5 and 5.0mg) with 6.25mg of hydrochlorothiazide. METHODS: One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial. RESULTS: The bisoprolol/hydrochlorothiazide combination reduced the initial mean values of systolic and diastolic blood pressures, respectively, from the 157.4mmHg and 98.8mmHg to 137.3mmHg and 87.4mmHg. At the end of the treatment period, 61% of the patients normalized blood pressure values (<90mmHg) and 22.9% of them had responded to the treatment, resulting in a total response rate (normalized + responsive) of 83.9% of cases. Adverse events were described only in 18.9% of the patients and dizziness and headache were the most common. There were no clinically significant changes on plasma levels of potassium, uric acid, glucose, or in the lipid profile. CONCLUSION: The combination of low dosages of bisoprolol and hydrochlorothiazide may be considered an effective, well tolerated and rational alternative for the initial treatment of the patients with mild to moderate hypertension.
European Journal of Nuclear Medicine and Molecular Imaging | 1992
Edwaldo E. Camargo; Fausto Haruki Hironaka; Maria Clementina Pinto Giorgi; José Maria Soares-Jr; J. Claudio Meneguetti; Rubens Abe; Cecil Chow Robilotta; Agda Cecília Leite Munhoz; Heddi Checchi; José Antonio Franchini Ramirez; Fúlvio Pileggi
To determine the role of rest and stress gated technetium-99m methoxyisobutylisonitrile (sestamibi), in the detection of coronary artery disease, routine Fourier analysis of these images was performed with the best septal left anterior oblique (LAO) position of 20 patients (17 men, 3 women; aged 40–75 years) who also underwent rest or redistribution/stress single photon emission tomography (SPET) (99mTc-sestamibi and Thallium-201), gated blood pool imaging and coronary angiogram. There were 6 patients with single-vessel disease, 6 with two-vessel disease, 4 with three-vessel disease, 2 with coronary spasms, 1 with a patent graft and 1 with anginal episodes but a normal angiogram result. Three normal volunteers (2 women, 1 man; aged 24–26 years) also had rest and stress gated blood pool as well as rest and stress gated 99mTc-sestamibi imaging. Rest and stress 99mTc-ses-tamibi amplitude and phase images depicted regional myocardial wall shortening from the outer layer of the myocardium to the center of the left ventricle as follows a high amplitude halo of maximal negative count rate variaton; a circular thinner halo of negligible amplitude; a central region of maximal positive count rate variation, as the images evolved from end-diastole to end-systole. Similar patterns with regional differences represented abnormal myocardial wall shortening. (99mTc-sestamibi and 201T1 SPET) images were in agreement in 90% of the patients and 92% of myocardial regions. 201T1 SPET detected 83% of angiographically proven lesions, as compared with 80% for 99mTc-setamibi SPET and 80% for the amplitude images. The amplitude images demonstrated a larger number of other abnormalities not predicted on the angiogram, probably because they were able to detect regions with a potential for flow improvement and transient regional wall shortening abnormalities. Amplitude and phase analyses of gated rest and stress 99mTc-ses-tamibi images are easy to perform and may become an important adjunct to (99mTc-sestamibi SPET) images for a complete evaluation of both regional myocardial perfusion and regional contractile function using a single tracer.
Arquivos Brasileiros De Cardiologia | 2004
Angela Maria Geraldo Pierin; Antônio Silveira Sbissa; Armando da Rocha Nogueira; Ayrton Pires Brandão; Cibeli I. Saad Rodrigues; Edgar Pessoa de Mello; José Xavier de Mello Filho; Luiz Carlos Bodanese; Paulo Toscano; Sebastiäo Rodrigues Ferreira Filho; Agostinho Tavares; Antonio Carlos Lopes; Jorge Pinto Ribeiro; José Carlos Aydar Ayoub; José Márcio Ribeiro; Luiz Introcaso; Marcelo Corrêa; Mario Fernando de Camargo Maranhäo; Pedro Jabur; Raimundo M. Nascimento; Roberto de Sá Cunha; Rogério Andrade Mulinari; Adriana Avila; Clóvis Oliveira Andrade; João Carlos Rocha; Margarida Maria Veríssimo Lopes; Maria Cecília G. Marinho Arruda; Maria Fátima Azevedo; Maria Helena C. Carvalho; Marilda Novaes Lipp
Arquivos Brasileiros De Cardiologia | 1986
Whady Hueb; José Antonio Franchini Ramirez; Giovanni Bellotti; Fabio Biscegli Jatene; Ana Neri Epitácio Pereira Miyazato; Fúlvio Pileggi; Adib D Jatene
Rev. Soc. Bras. Clín. Méd | 2012
Vitor Emer Egypto Rosa; Robinson Tadeu Munhoz; Antonio Carlos Pereira Barretto; José Antonio Franchini Ramirez
European Journal of Heart Failure Supplements | 2008
Christiano Pereira Silva; C.H. Del Carlo; M.O. Tavares; M. Occhiai; Airton R. Scipioni; C. Strunz‐Cassaro; José Antonio Franchini Ramirez; Antonio Carlos Pereira Barretto
Consenso Brasileiro de Hipertensäo Arterial | 1999
Osvaldo Kohlmann Junior; Artur Beltrame Ribeiro; Daniel Rinaldi; Dante Marcelo Artigas Giorgi; Emilton Lima Júnior; Fernando Antonio de Almeida; Gilson Soares Feitosa; Hélio Bernardes Silva; Joäo Cesar Mendes Moreira; José Antonio Franchini Ramirez; Marcelo Marcondes Machado; Maria Helena Catelli Carcalho; Michel Batlouni; Oswaldo Luiz Ramos; Roberto da Silva Franco; Wille Oigman
Rev. paul. med | 1987
Ronaldo Ducceschi Fontes; Hélio Poço Ferreira; David Everson Uip; Floracy Gomes Ribeiro; Pablo Maria Alberto Pomerantzeff; Pedro Carlos Piantino Lemos; Fabio Biscegli Jatene; Arlindo Riso; Flávio Tarasoutchi; Max Grinberg; José Antonio Franchini Ramirez; Noedir A. G Stolf; Adib Domingos Jatene